Focused On-demand Library for Ephrin type-B receptor 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P54762

UPID:
EPHB1_HUMAN

ALTERNATIVE NAMES:
ELK; EPH tyrosine kinase 2; EPH-like kinase 6; Neuronally-expressed EPH-related tyrosine kinase; Tyrosine-protein kinase receptor EPH-2

ALTERNATIVE UPACC:
P54762; A8K593; B3KTB2; B5A969; O43569; O95142; O95143; Q0VG87

BACKGROUND:
The Ephrin type-B receptor 1, with aliases such as ELK and Neuronally-expressed EPH-related tyrosine kinase, is a receptor tyrosine kinase integral to the forward and reverse signaling pathways. It engages with EFNB1, EFNB2, and EFNB3 ligands to regulate crucial processes like angiogenesis, chemotaxis, and polarity of hippocampus neural progenitors. Its role extends to guiding retinal axon guidance and influencing the development of dendritic spines and synapse formation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Ephrin type-B receptor 1 could open doors to potential therapeutic strategies. Given its critical functions in angiogenesis and neural progenitor regulation, it holds promise for therapeutic interventions in vascular and neurodegenerative diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8143 of 8789